[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555992":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":60,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ICI group",null,"Patients that receive immune checkpoint inhibitors",[13,14],"Diagnostic Test: Coronary computed tomography angiography (CCTA) at baseline","Diagnostic Test: Coronary computed tomography angiography (CCTA) after 1 year",{"label":16,"type":10,"description":17,"interventionNames":18},"Non-ICI group","Patients with similar malignancies, who do not receive immune checkpoint inhibitors",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","Coronary computed tomography angiography (CCTA) at baseline","Detailed imaging of coronary arteries",[9,16],{"type":21,"name":26,"description":23,"armGroupLabels":27,"otherNames":10},"Coronary computed tomography angiography (CCTA) after 1 year",[9,16],[29],{"name":30,"affiliation":31,"role":32},"H.W.M. van Laarhoven, Prof. Dr.","secretariaat.oncologie@amsterdamumc.nl","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"A Strijdhorst","CONTACT","+31 205665975","a.strijdhorst@amsterdamumc.nl",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Amsterdam UMC","RECRUITING","Amsterdam","North Holland","1105AZ","Netherlands","NL",{"type":49,"coordinates":50},"Point",[51,52],4.88969,52.37403,{"lat":52,"lon":51},[55],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Hanneke W. M. van Laarhoven","Principal Investigator",[61],{"name":41,"class":6},"100555992","immune-checkpoint-inhibitor-associated-cardiovascular-adverse-events-in-patients-with-cancer-100555992",false,"NCT06519292","Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer","ITHACA","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma\n* Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)\n* Age ≥ 50 years\n\nExclusion Criteria:\n\n* ICI therapy in previous 12 months\n* Suspected or confirmed viral, fungal, or bacterial infectious disease\n* Use of immunosuppressive therapy prior to ICI start\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Known allergy to iodinated contrast agents\n* Atrial fibrillation","ALL","50 Years",{"count":72,"type":73},214,"ESTIMATED","OBSERVATIONAL","Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system in the body. Recently, concerns have also risen about cardiovascular effects of ICI. Retrospective studies showed an 4-5 times increased risk of developing an arterial thromboembolic event.\n\nThe mechanisms driving the ICI-associated risks of arterial thromboembolic events such as myocardial infarction and stroke, are unclear. Since the risk of a thromboembolism appears to be increased already during the first months after initiation of ICI, immune-related hypercoagulability or (autoimmune) antiphospholipid antibodies may play a role, but data to support this are lacking. The longer-term risk of arterial thromboembolism may be predominantly driven by (accelerated) atherosclerosis, a chronic low-grade inflammatory disease of the larger arteries. Therefore, this study evaluates the effect of ICI on progression of coronary non-calcifid plaque volume by using computed tomography angiography (CCTA).",[77,78,79,80,81,82,83],"Cardiovascular Diseases","Arterial Thrombosis","Myocardial Infarction","Stroke","Coronary Artery Disease","Atherosclerosis","Cancer",[85,86,87],"immune checkpoint inhibitors","cardiovascular disease","atherosclerosis","2025-05-20",{"date":90,"type":91},"2025-05-22","ACTUAL",{"date":93,"type":91},"2023-01-25",{"date":95,"type":73},"2025-12-31",{"name":58,"class":6},1]